This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haas, N. B. Articles by Hudes, G. R. Search for Related Content PubMed PubMed Citation Articles by Haas, N. B. Articles by Hudes, G. R.

Weekly Bryostatin-1 in Metastatic Renal Cell Carcinoma

A Phase II Study¹

Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [N. B. H., M. S., N. L., L. L., G. Y., I. D. J., J. B., H. W., A. R., G. R. H.]; Pinnacle Cancer Center, Harrisburg, Pennsylvania [R. G.]; and Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland [A. M.]

Purpose: We conducted a Phase II trial of bryostatin-1, an inhibitor of protein kinase C, in advanced renal cell carcinoma to measure toxicity, response rate, time to progression, and induction of cytokines.

Experimental Design: A total of 32 patients (26 male and 6 female) received bryostatin-1 at 35–40 µg/m² i.v. over 1 h on days 1, 8, and 15 of each 4-week cycle. Plasma interleukin-6, tumor necrosis factor-, and C-reactive protein levels were assayed pretreatment, 1 and 23 h after completion of bryostatin-1 infusion at weeks 1 and 5.

Results: Cycles (102) of bryostatin-1 were given (median 2, range 1–8). The most common grade 1 or 2 toxicities were myalgias (46.8%), fatigue (59.3%), and dyspnea (18.8%). Grade 3–4 toxicity included myalgias (40.6%), ataxia (9.3%), and dyspnea (15.6%). Four (12%) patients experienced cardiac events while on study (cardiac arrhythmias and congestive heart failure occurred in 2 patients, and 2 patients had fatal cardiac arrests). Of 32 patients evaluable for response, 2 (6.3%) had partial responses lasting 9 with 6 months. A total of 15 patients (46.8%) had stable disease, and 6 (18.8%) patients had stable disease for 6 months. Plasma interleukin-6 increased 2-fold over baseline measurements in 5 of 17 patients (29.4%) but did not correlate with response or toxicity.

Conclusions: Although weekly bryostatin-1 at 35–40 µg/m² produced a low proportion of objective responses, prolonged (>6 months) stable disease or partial remission in 25% of patients suggests that this agent, or other inhibitors of protein kinase C, may have a role in the treatment of renal cell carcinoma, perhaps in combination with other agents.

This article has been cited by other articles:

				S. Mohanty, J. Huang, and A. Basu Enhancement of Cisplatin Sensitivity of Cisplatin-Resistant Human Cervical Carcinoma Cells by Bryostatin 1 Clin. Cancer Res., September 15, 2005; 11(18): 6730 - 6737. [Abstract] [Full Text] [PDF]

				T. Ahmad and T. Eisen Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6388S - 6392S. [Abstract] [Full Text] [PDF]

				M. L. Amador, J. Jimeno, L. Paz-Ares, H. Cortes-Funes, and M. Hidalgo Progress in the development and acquisition of anticancer agents from marine sources Ann. Onc., November 1, 2003; 14(11): 1607 - 1615. [Full Text] [PDF]